Literature DB >> 13969657

The vivo interaction between staphylococcus bacteriophage and Staphylococcus aureus.

P F BARTELL, I S THIND, T ORR, W S BLAKEMORE.   

Abstract

Staphylococcus bacteriophage 81 is capable of in vivo interaction with Staphylococcus aureus, Type 80/81. This is immediately made evident by increased levels of bacteriophage and concomitant survival of 81 per cent infected mice. The reaction is dependent upon the use of active, type-specific bacteriophage. The maximal protective effect is observed at a bacteriophage to bacteria ratio of 1:2 and decreased quantities of bacteriophage result in decreased protection. Time and sequence of administration are also determining factors. It is evident that bacteriophage administered intravenously is capable of interaction with the infecting bacterial cell at the site of infection. In vivo produced bacteriophage is apparently eliminated or otherwise rendered nondetectable fairly rapidly, occurring within a period of 5 to 10 days. However, it appears that host defense mechanisms are stimulated in the process and actively play a protective role against subsequent challenge inocula administered up to 3 weeks later.

Entities:  

Keywords:  STAPHYLOCOCCAL PHAGES; STAPHYLOCOCCUS

Mesh:

Year:  1963        PMID: 13969657      PMCID: PMC2137576          DOI: 10.1084/jem.118.1.13

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  1 in total

1.  Staphylococcal bacteriophage in experimental infection in mice.

Authors:  W R MUIR; W S BLAKEMORE
Journal:  Surg Forum       Date:  1960
  1 in total
  3 in total

1.  Adsorption of staphylococcal bacteriophage by milk proteins.

Authors:  N K Das; R T Marshall
Journal:  Appl Microbiol       Date:  1967-09

Review 2.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Authors:  Krystyna Dąbrowska; Stephen T Abedon
Journal:  Microbiol Mol Biol Rev       Date:  2019-10-30       Impact factor: 11.056

Review 3.  Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review.

Authors:  Krystyna Dąbrowska
Journal:  Med Res Rev       Date:  2019-03-19       Impact factor: 12.944

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.